Contact us

Our latest news

Back to news >

Linette Ruston joins Seda in ADME role

We are delighted to announce the appointment of Dr. Linette Ruston as Senior Principal Scientist, ADME. Linette holds a BSc (Hons) and PhD in Chemistry from the Universities of Glasgow and Edinburgh, respectively.  She is an experienced Biopharmaceutics and DMPK scientist having spent 17+ years with AstraZeneca where she held roles in Discovery and Early Pharmaceutical Development. Linette provided expert physicochemical, ADME and Biopharmaceutics input into compound design and selection, and applied knowledge of in vitro, in silico and in vivo models to enable material choice and project progression from discovery to early clinical development.  Her current focus is on translation of DMPK/PD and biopharmaceutics understanding into meaningful product and clinical study design within Seda.

Linette will play a key role in provision of our DMPK consultancy which includes:

  • Advice on compound profiling at all stages of drug discovery
  • Identification of issues and compound ranking
  • Analysis of data and linking compound performance to molecule design
  • Compound design to overcome DMPK issues while maintaining activity (multiparameter optimisation)
  • Characterisation of compound absorption, distribution, metabolism, and excretion attributes, including design of bespoke in vitro and in vivo studies to answer the specific compound questions
  • Interpretation and scaling of pre-clinical PK data facilitating prediction of human PK profiles
  • Human dose predictions
  • Identification of compound liabilities and performing risk assessments
  • Selection of appropriate vendors and data providers

Seda’s DMPK consultancy offering recognises the vital importance of understanding the drug metabolism and pharmacokinetic (DMPK) properties of compounds to identify candidate molecules with suitable properties for development such as:

  • Human dose that is realistic to develop
  • Will remain in the body for long enough / or activity will last long enough so that patient dosing does not have to be too frequent
  • Manageable interaction profile with other drugs the patient will be taking

Please join us in welcoming Linette to the team.